- Home
- SGLY vs ADTX Comparison
SGLY vs ADTX Comparison
Compare SGLY & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- ADTX
- Stock Information
- Founded
- SGLY 2001
- ADTX 2017
- Country
- SGLY United States
- ADTX United States
- Employees
- SGLY N/A
- ADTX N/A
- Industry
- SGLY
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- ADTX Health Care
- Exchange
- SGLY Nasdaq
- ADTX Nasdaq
- Market Cap
- SGLY 5.8M
- ADTX 5.3M
- IPO Year
- SGLY 2008
- ADTX 2020
- Fundamental
- Price
- SGLY $0.83
- ADTX $0.09
- Analyst Decision
- SGLY
- ADTX
- Analyst Count
- SGLY 0
- ADTX 0
- Target Price
- SGLY N/A
- ADTX N/A
- AVG Volume (30 Days)
- SGLY 3.3M
- ADTX 150.6M
- Earning Date
- SGLY 02-19-2025
- ADTX 04-15-2025
- Dividend Yield
- SGLY N/A
- ADTX N/A
- EPS Growth
- SGLY N/A
- ADTX N/A
- EPS
- SGLY N/A
- ADTX N/A
- Revenue
- SGLY $2,255,541.00
- ADTX $212,107.00
- Revenue This Year
- SGLY N/A
- ADTX $95.61
- Revenue Next Year
- SGLY N/A
- ADTX $1,584.79
- P/E Ratio
- SGLY N/A
- ADTX N/A
- Revenue Growth
- SGLY N/A
- ADTX N/A
- 52 Week Low
- SGLY $0.66
- ADTX $0.07
- 52 Week High
- SGLY $7.65
- ADTX $218.00
- Technical
- Relative Strength Index (RSI)
- SGLY 36.06
- ADTX 36.78
- Support Level
- SGLY $0.78
- ADTX $0.07
- Resistance Level
- SGLY $0.95
- ADTX $0.16
- Average True Range (ATR)
- SGLY 0.17
- ADTX 0.02
- MACD
- SGLY -0.00
- ADTX 0.01
- Stochastic Oscillator
- SGLY 18.80
- ADTX 28.49
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.